Waldenström’s macroglobulinemia
| Autor: | Bart Barlogie, K. R. Desikan, Dhodapkar Mv |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
medicine.medical_specialty Purine analogue Antineoplastic Agents Asymptomatic Antibodies Monoclonal Murine-Derived Maintenance therapy Refractory Interferon Internal medicine medicine Humans Pharmacology (medical) Clinical Trials as Topic business.industry Beta-2 microglobulin Antibodies Monoclonal Interferon-alpha Macroglobulinemia Plasmapheresis Combined Modality Therapy Survival Rate Cladribine Chlorambucil Neoplasm Recurrence Local Waldenstrom Macroglobulinemia Stem cell medicine.symptom Rituximab beta 2-Microglobulin business Vidarabine medicine.drug |
| Zdroj: | Current Treatment Options in Oncology. 1:97-103 |
| ISSN: | 1534-6277 1527-2729 |
| DOI: | 10.1007/s11864-000-0054-5 |
| Popis: | Waldenström's macroglobulinemia (WM) is a clinical syndrome with diverse prognoses, and not all patients require therapy at diagnosis. Serum beta2 microglobulin is a major prognostic determinant, and asymptomatic patients with low beta2 microglobulin levels and preserved hemoglobin can be observed over long periods without therapy. Low-dose alkylating agents and purine analogs are commonly employed as initial therapy but rarely yield complete remissions. Patients who are refractory to or have relapse after alkylator or purine analogue therapy can be salvaged with purine analogs. Improvement in outcome demands a comprehensive approach aimed at increasing and sustaining complete remissions. Such an approach should probably employ Rituxan (IDEX Pharmaceuticals, La Jolla, CA) in conjunction with induction therapy, peripheral stem cell procurement before purine analog therapy, and high-dose therapy followed by maintenance therapy with interferon. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink